{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-132991","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2021-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.889930+00:00","generated_at":"2026-06-28T14:56:55.124061+00:00","sec_items":["3.01","5.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cellectar receives Nasdaq non-compliance notice; appoints Laurence Reilly as interim CMO","bullets":["Received Nasdaq deficiency notice for bid price below $1 for 30 consecutive business days; has 180 days until May 2, 2022 to cure.","Appointed Laurence Reilly as interim CMO effective Nov 2; John Friend departs for personal reasons after transition.","Company asserts sufficient cash into 2H 2023; focused on iopofosine I-131 registrational trial in WM and other programs.","Dr. Reilly previously consulted for Cellectar; experience at Pfizer and Avillion; will oversee clinical development."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-132991","json":"https://secwatch.observer/filing/0001104659-21-132991.json","markdown":"https://secwatch.observer/filing/0001104659-21-132991.md","text":"https://secwatch.observer/filing/0001104659-21-132991.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465921132991/0001104659-21-132991-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465921132991/tm2131707d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T14:56:55.124061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60e19344fa","claim":"John Friend departed as Chief Medical Officer at Cellectar Biosciences, Inc..","evidence_excerpt":"Dr. Reilly succeeds John Friend, MD, who is stepping down but will stay on through mid-November to finalize the ongoing transition.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465921132991/0001104659-21-132991-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"stepping down"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"d2bffa2da5","claim":"Laurence Reilly was appointed as Interim Chief Medical Officer at Cellectar Biosciences, Inc..","evidence_excerpt":"On November 2, 2021, the Company appointed Dr. Laurence Reilly as Interim Chief Medical Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465921132991/0001104659-21-132991-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}